Tuesday - May 6, 2025
BLOOMFIELD, Conn., July 10, 2023 /PRNewswire/ -- The Cigna Group (NYSE: CI) today released its 2022 environmental, social, and governance (ESG) report outlining the organization's commitment to transforming the ecosystem of health into one that is sustainable, accessible, and equitable—advancing better health for all.
"Driven by our purpose, we approach today's global health challenges with urgency, optimism and a confidence that we will continue to make a positive impact. This year's publication, which is our 10th annual report, is a reflection of the passion and hard work that our colleagues around the world do each and every day," said Nancy Ryan, global ESG lead at The Cigna Group. "While our efforts are ongoing, this report celebrates the goals we've met and inspires us to do even more as we build a healthier world for all."
The Cigna Group's ESG framework is built on four pillars: Healthy Society, Healthy Workforce, Healthy Environment, and Healthy Company. The following are just a few examples of the work being done across the organization to improve the health and environmental outcomes of our communities and customers:
In addition to reporting on the organization's progress to date, this year's report also includes key performance indicators that will be disclosed in future reports for each of area of focus to help demonstrate additional progress.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 190 million customer relationships around the world. Learn more at thecignagroup.com.
Media Contact
Meaghan MacDonald
(860) 840-1212
meaghan.macdonald@cigna.com
Last Trade: | US$333.01 |
Daily Change: | -1.74 -0.52 |
Daily Volume: | 1,446,385 |
Market Cap: | US$92.630B |
January 30, 2025 October 31, 2024 September 12, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load